全文获取类型
收费全文 | 9010篇 |
免费 | 841篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 274篇 |
妇产科学 | 234篇 |
基础医学 | 1207篇 |
口腔科学 | 204篇 |
临床医学 | 1210篇 |
内科学 | 1601篇 |
皮肤病学 | 98篇 |
神经病学 | 861篇 |
特种医学 | 191篇 |
外科学 | 1219篇 |
综合类 | 204篇 |
一般理论 | 13篇 |
预防医学 | 1138篇 |
眼科学 | 175篇 |
药学 | 614篇 |
中国医学 | 10篇 |
肿瘤学 | 540篇 |
出版年
2023年 | 97篇 |
2022年 | 63篇 |
2021年 | 302篇 |
2020年 | 225篇 |
2019年 | 306篇 |
2018年 | 317篇 |
2017年 | 253篇 |
2016年 | 231篇 |
2015年 | 239篇 |
2014年 | 337篇 |
2013年 | 418篇 |
2012年 | 636篇 |
2011年 | 649篇 |
2010年 | 314篇 |
2009年 | 250篇 |
2008年 | 475篇 |
2007年 | 432篇 |
2006年 | 382篇 |
2005年 | 375篇 |
2004年 | 341篇 |
2003年 | 297篇 |
2002年 | 287篇 |
2001年 | 147篇 |
2000年 | 152篇 |
1999年 | 147篇 |
1998年 | 54篇 |
1996年 | 53篇 |
1995年 | 44篇 |
1994年 | 48篇 |
1992年 | 123篇 |
1991年 | 118篇 |
1990年 | 128篇 |
1989年 | 127篇 |
1988年 | 117篇 |
1987年 | 100篇 |
1986年 | 117篇 |
1985年 | 106篇 |
1984年 | 82篇 |
1983年 | 67篇 |
1982年 | 52篇 |
1981年 | 45篇 |
1980年 | 39篇 |
1979年 | 63篇 |
1978年 | 54篇 |
1976年 | 47篇 |
1974年 | 42篇 |
1973年 | 51篇 |
1972年 | 39篇 |
1969年 | 44篇 |
1967年 | 38篇 |
排序方式: 共有9861条查询结果,搜索用时 906 毫秒
1.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
2.
3.
4.
5.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
6.
7.
8.
9.
10.
Most prosthetic joint infections (PJI) are due to wound contamination at the time of surgery. Some infections occur due to the hematogenous spread of bacteria from distant sites of infection. A review of the literature fails to associate PJI with transient bacteremias from invasive dental procedures. Several authors have described conditions which, they believe, render patients with prosthetic joints more at risk for infection. Prosthetic joint patients with these "high risk" conditions have the same types of infecting organisms as other patients with PJI. This indicates that the infecting bacteria are from wound contamination or distant sites of infection and not related to dental procedure bacteremias. Based on this review, antibiotic prophylaxis is not indicated for patients with prosthetic joints when receiving invasive dental procedures, since there is no proven benefit and there are known risks involved with the use of antibiotics. However, the American Dental Association (ADA) and the American Academy of Orthopaedic Surgeons (AAOS), in an advisory statement, suggest prophylaxis for "high risk" patients. The ADA and AAOS recommend a single dose of amoxicillin, cephradine, or clindamycin when prophylaxis is selected. The dentist is ultimately responsible for making treatment recommendations for his or her patients. 相似文献